Accordingly, two meta-analyses showed a risk of 3.3 (95% CI, 2.74–3.99) (1, 15) and 2.86 (95% CI, 2.00–4.10) (12) for genital infection with the use of SGLT2 inhibitor in type 2 diabetes mellitus patients. This evidence concerns the gene SLC5A2 and diabetes mellitus.